Skip to content
    venBio logo

    venBio

    San Francisco, California, United StatesFounded 2011
    www.venbio.comLinkedIn
    Biotech & Life SciencesHealthcare

    venBio is a life sciences venture capital firm founded in 2011 that partners with industry leaders to build game-changing medicines and technologies, focusing on novel therapeutics for unmet medical needs. The firm has raised nearly $2 billion in total committed capital since inception and is currently investing out of its fifth fund of approximately $528 million. venBio takes an active role in portfolio companies, providing strategic guidance across research, clinical, and business activities from early to late stages of clinical development.

    62% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $92.2M (across 43 rounds with reported amounts).

    Find people at venBio on Goldilocks AI

    Portfolio

    41

    Fund Size

    $528M

    Top Stage

    Series A

    Last 12 Mo

    1

    Team

    Corey Goodman, PhD

    Corey Goodman, PhD

    Co-founder and Managing Partner

    Robert Adelman, MD

    Robert Adelman, MD

    Co-founder and Emeritus Managing Partner

    Aaron Royston, MD, MBA

    Aaron Royston, MD, MBA

    Managing Partner

    Richard Gaster, MD, PhD

    Richard Gaster, MD, PhD

    Managing Partner

    Yvonne Yamanaka, PhD

    Yvonne Yamanaka, PhD

    Partner

    Parthiv Patel

    Parthiv Patel

    Analyst

    Daniel Teichmann

    Daniel Teichmann

    Controller

    David Pezeshki, CFA, CPA

    David Pezeshki, CFA, CPA

    Chief Financial Officer

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    48 investments
    CompanyRoundAmountDate
    Artiva Biotherapeutics logoArtiva BiotherapeuticsSeries B$120MJan 2026
    35 Pharma logo35 PharmaSeries C$53MNov 2024
    Axonis logoAxonisSeries A$115MOct 2024
    Vicebio logoVicebioSeries B$100MSep 2024
    Attovia Therapeutics logoAttovia TherapeuticsSeries B$105MMay 2024
    Aeovian Pharmaceuticals logoAeovian PharmaceuticalsUnknown$50MMar 2024
    Alumis logoAlumisSeries C$259MMar 2024
    AAxonis TherapeuticsSeries A$115MJan 2024
    Abdera Therapeutics logoAbdera TherapeuticsSeries B$110MJan 2023
    Entact Bio logoEntact BioSeries A$81MDec 2022
    AAcelyrin, IncSeries C$300MSep 2022
    AAcelyrinSeries C$300MSep 2022
    IImmPACT Bio USASeries B$111MJan 2022
    NNorthsea TherapeuticsSeries C$80MDec 2021
    AAblaze PharmaceuticalsSeries A$75MNov 2021
    HistoWiz logoHistoWizSeries A$32MOct 2021
    Histowiz logoHistowizSeries A$32MOct 2021
    InBrace logoInBraceSeries D$102MSep 2021
    Neurogastrx logoNeurogastrxSeries B$60MAug 2021
    Tallac Therapeutics logoTallac TherapeuticsSeries A$62MDec 2020
    SStargazer PharmaceuticalsSeries A$57MNov 2020
    AAttralusSeries A—Sep 2020
    Nflection Therapeutics logoNflection TherapeuticsSeries A$20MJun 2020
    ALX Oncology logoALX OncologyUnknown$105MFeb 2020
    ALX Oncology logoALX OncologySeries C—Jan 2020
    Page 1 of 2

    Top Co-Investors

    Vivo Capital17 shared
    Cormorant Asset Management14 shared
    Surveyor Capital12 shared
    Samsara BioCapital10 shared
    Sofinnova Partners9 shared
    OrbiMed8 shared
    Logos Capital8 shared
    Marshall Wace8 shared
    Foresite Capital7 shared
    Omega Funds6 shared
    Decheng Capital6 shared
    Alexandria Venture Investments5 shared
    Cowen Healthcare Investments5 shared
    Forbion4 shared
    Westlake Village BioPartners4 shared
    Tybourne Capital Management4 shared
    Canaan Partners3 shared
    F-Prime Capital3 shared
    Frazier Life Sciences3 shared
    HBM Healthcare Investments3 shared

    Last updated: 8 September 2026